Open AccessBreaking Down the Evidence for Bevacizumab in Ovarian Cancer
Author(s) -
Shu Catherine A.,
Konner Jason A.
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0302
Subject(s) - bevacizumab , medicine , ovarian cancer , oncology , chemotherapy , cancer
Bevacizumab has been FDA‐approved for use in combination with single‐agent chemotherapy for platinum‐resistant ovarian cancer; however, its optimal role remains unclear. In this editorial, the timing, efficacy, safety, and rationale for use of bevacizumab in ovarian cancer are discussed.